Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Isoproterenol is used as a cardiac stimulant in electrophysiology studies (EP). Preliminary data suggests that administration of isoproterenol increases the Bispectral index (BIS). BIS is used to monitor neuronal signals under anesthesia. The BIS level is suggested to correspond to the level of consciousness. We hypothesize that isoproterenol increases BIS values because it increases the patient's level of consciousness through its central nervous system (CNS) stimulatory effects. In this study, we will administer increasing doses of isoproterenol to EPS patients. We will measure the BIS levels continuously before and after isoproterenol administration. In addition, we will test the level of awareness of patients by their response to a modified isolated forearm technique.
| Condition | Intervention |
|---|---|
|
Isoproterenol Bispectral Index (BIS) Electrophysiology Studies (EPS) |
Drug: Isoproterenol |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study to Measure BIS and Awareness in Patients Undergoing EPS With Isoproterenol |
- We will measure the BIS level and test the level of awareness of patients by their responses to the isolated forearm technique test before and after isoproterenol administration. [ Time Frame: During time of EP studies. ] [ Designated as safety issue: No ]We hypothesize that isoproterenol increases BIS values because it increases the patient's level of consciousness through its central nervous system (CNS) stimulatory effects. In this study, we will administer increasing doses of isoproterenol to EPS patients. We will measure the BIS levels continuously before and after isoproterenol administration. In addition, we will test the level of awareness of patients by their response to the isolated forearm technique.
| Enrollment: | 25 |
| Study Start Date: | August 2009 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Isoproterenol, BIS, electrophysiology testing
30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
|
Drug: Isoproterenol
Application of isoproterenol
|
Detailed Description:
Isoproterenol is a direct acting Beta-1 and Beta-2 agonist useful for its effects on bronchodilation and myocardial contractility. Its CNS side effects include nervousness, headache, dizziness, restlessness, insomnia, anxiety, tension, blurring of vision, fear, and excitement. (1) In addition to our preliminary data, two case reports show an increase in BIS with administration of isoproterenol. (2, 3) Our hypothesis is that administration of isoproterenol will increase the level of consciousness of the patient as reflected in the BIS reading.
The BIS Vista TM Monitor is a non-invasive device that measures the electrical activity of the brain. It computes a number between 0 and 100 which corresponds to a level of consciousness which is known as the Bispectral (BIS) value. Using the BIS value to guide administration of anesthetic medication, clinicians can make informed decisions for optimal anesthesia. This technology has the potential to prevent over sedation, but is currently not a standard monitoring device. (4, 5)
Another approach to evaluating the level of consciousness of anesthetized patients is to assess their ability to form memories or recall events which occurred while under anesthesia. Conscious recall is the first to disappear with decreasing levels of consciousness. A BIS of 60 or less has been shown in various studies to be sufficient to prevent conscious recall in the vast majority of patients. We propose to use a modified isolated forearm technique test in which the patient is asked to squeeze an observer's hand during anesthesia to ascertain if awareness can occur without recall at a BIS of 60 to 70. (6) Implicit memory in which there is no conscious recall or evaluation of awareness can be assessed by word stem completion tests and has been shown to occur with a BIS as low as 40 - 60 although these results are not consistent across all studies. (7)
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled for EP studies under general anesthesia will participate in the study
Exclusion Criteria:
- Patients with neuromuscular disease precluding the use of succinylcholine will be excluded.
- Patient or cardiologist refusal
Contacts and Locations| United States, New York | |
| NYU Langone Medical Center, Department of Anesthesiology | |
| New York City, New York, United States, 10016 | |
| Principal Investigator: | Pat Linton, MD | NYU School of Medicine |
More Information
No publications provided
| Responsible Party: | New York University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01377636 History of Changes |
| Other Study ID Numbers: | H#: 09-0440 |
| Study First Received: | March 22, 2010 |
| Last Updated: | February 27, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by New York University School of Medicine:
|
Isoproterenol Bispectral index (BIS) electrophysiology studies (EPS) |
Additional relevant MeSH terms:
|
Isoproterenol Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Bronchodilator Agents |
Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Cardiotonic Agents Cardiovascular Agents Sympathomimetics Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013